Saturday 17 October 2026
Export PRCT’s income statement to Excel — free account
PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024. In the quarter to June 2026, revenue grew 19.3%, EPS fell 34.3%, free cash flow fell 24.4% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
17.57
0.58
−3.20%
Follow PRCT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 3 | 4 | 6 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
6.44 | 18.46 | 8.36 | 8.58 | 3.13 | — | — | — |
P/S ratio |
5.67 | 18.70 | 14.38 | 23.42 | 11.96 | 0.00 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
2.18 | 3.92 | 1.84 | 1.45 | 6.43 | (1.80) | (11.71) | — |
Beneish M-Score |
(2.86) | (1.90) | (0.98) | 0.65 | (0.49) | — | — | — |
P/Operating CF |
(169.21) | (129.58) | (78.98) | (69.77) | (25.02) | (18.18) | (18.18) | — |
P/B ratio |
4.78 | 10.43 | 6.98 | 8.91 | 1.54 | 0.00 | 0.00 | — |
Price to Tangible BV |
4.79 | 10.46 | 7.01 | 8.98 | 1.55 | 0.00 | 0.00 | — |
EV/Sales |
4.92 | 17.45 | 12.88 | 21.18 | 4.68 | 0.00 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(30.92) | (39.48) | (16.24) | (19.77) | (2.82) | (1.70) | (1.70) | — |
EV/FCF |
(25.96) | (37.80) | (13.17) | (19.14) | (2.79) | (1.69) | (1.69) | — |
Quick Ratio |
5.62 | 7.85 | 6.65 | 6.74 | 19.01 | 7.00 | 6.35 | — |
Current Ratio |
6.85 | 9.07 | 7.63 | 7.73 | 20.08 | 7.59 | 7.42 | — |
Net Debt/EBITDA |
2.41 | 3.07 | 1.94 | 2.15 | 4.93 | 1.06 | 0.45 | — |
Debt/Assets |
10.16% | 10.01% | 13.15% | 17.82% | 15.91% | 41.63% | 37.46% | 0.00% |
Debt/Equity |
0.14 | 0.13 | 0.19 | 0.28 | 0.20 | 0.86 | 0.79 | — |
Asset Turnover |
0.59 | 0.48 | 0.38 | 0.23 | 0.15 | 0.08 | 0.20 | — |
Operating CF/Net income |
0.51 | 1.09 | 1.02 | 0.92 | 0.96 | 0.91 | 1.04 | — |
Capex/Depreciation |
(1.46) | (0.84) | (6.62) | (0.93) | (0.18) | (0.08) | 0.00 | — |
Interest Coverage |
(28.96) | (23.09) | (27.33) | (15.57) | (9.32) | (9.09) | (46.50) | — |
| (24.89%) | (26.77%) | (44.32%) | (37.55%) | (142.17%) | 32.45% | 25.69% | — | |
| (18.34%) | (19.48%) | (29.66%) | (26.97%) | (25.85%) | (56.41%) | (135.41%) | — | |
ROIC |
(49.56%) | (49.51%) | (88.89%) | (170.70%) | (206.72%) | (225.01%) | 0.00% | — |
Return on Tangible Assets |
(23.03%) | (20.07%) | (31.76%) | (35.43%) | (19.00%) | (50.98%) | (80.97%) | — |
Average Days of Receivables |
98.97 | 135.75 | 129.65 | 74.31 | 47.26 | 73.26 | 65.02 | — |
Research and Development Expense of Revenue |
23.14% | 27.75% | 35.57% | 38.63% | 55.10% | 210.90% | 213.11% | — |
Selling, General and Administrative Expense of Revenue |
74.28% | 76.35% | 96.76% | 118.42% | 148.05% | 392.28% | 462.28% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 | 0.00 |
Share Based Compensation of Revenue |
15.45% | 14.18% | 14.05% | 13.78% | 11.01% | 28.16% | 0.00% | — |
Graham Net Nets |
0.18 | 0.08 | 0.12 | 0.09 | 0.62 | 0.75 | 0.75 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(5.44%) | (2.19%) | (5.41%) | (4.95%) | (27.59%) | (24.26%) | (24.26%) | — |
Free Cash Flow Yield |
(3.34%) | (2.47%) | (6.80%) | (4.73%) | (14.05%) | (32.73%) | (32.73%) | — |
Revenue per Share |
5.55 | 4.31 | 2.88 | 1.69 | 2.09 | 2.11 | 0.14 | — |
Operating CF per Share |
(0.88) | (1.90) | (2.29) | (1.81) | (3.48) | (13.20) | (1.01) | — |
Capex per Share |
(0.17) | (0.08) | (0.53) | (0.06) | (0.04) | (0.06) | 0.00 | — |
Free Cash Flow per Share |
(1.05) | (1.99) | (2.82) | (1.87) | (3.51) | (13.26) | (1.01) | — |
Cash per Share |
5.16 | 6.40 | 5.44 | 5.01 | 18.47 | 27.34 | 0.97 | — |
Shareholders Equity per Share |
6.59 | 7.72 | 5.94 | 4.44 | 16.21 | 16.64 | 0.68 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
6.59 | 7.72 | 5.94 | 4.44 | 16.21 | 16.64 | 0.68 | — |
Free Cash Flow |
(58.34) | (103.62) | (133.21) | (83.03) | (57.93) | (48.58) | (43.82) | — |
Working Capital |
384.58 | 428.71 | 304.64 | 237.34 | 309.93 | 95.73 | 43.57 | — |
Capital Expenditures |
(9.36) | (4.41) | (25.21) | (2.65) | (0.59) | (0.23) | (7.61) | — |
Net Current Asset Value |
308.17 | 350.05 | 226.60 | 160.37 | 256.24 | 45.25 | 17.59 | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.03 | 0.02 | 0.19 | 0.04 | 0.02 | 0.03 | 0.00 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||
Depreciation/Fixed assets |
0.21 | 0.20 | 0.13 | 0.33 | 0.66 | 0.35 | 0.18 | — |
Cash ROIC |
(8.29%) | (13.13%) | (22.53%) | (17.49%) | (9.27%) | (22.75%) | (46.38%) | — |
Accounts Receivable Turnover |
3.69 | 3.40 | 4.28 | 7.60 | 11.47 | 5.83 | 4.66 | — |
Accounts Payable Turnover |
8.19 | 7.43 | 5.69 | 6.64 | 11.38 | 6.69 | 6.00 | — |
Inventory Turnover |
1.76 | 1.82 | 1.91 | 1.82 | 1.85 | 1.32 | 1.14 | — |
Average Days of Payables |
56.42 | 41.90 | 75.64 | 90.37 | 39.80 | 50.45 | 65.44 | — |
Days of Inventory on Hand |
230.74 | 234.57 | 222.76 | 274.68 | 257.88 | 281.68 | 303.00 | — |
Average Receivables |
83.51 | 65.94 | 31.82 | 9.87 | 3.01 | 1.32 | 1.32 | — |
Average Payables |
13.66 | 11.77 | 11.45 | 5.71 | 1.63 | 1.34 | 1.34 | — |
Average Inventory |
63.43 | 47.96 | 34.15 | 20.85 | 10.04 | 6.81 | 7.08 | — |
Average Assets |
521.05 | 469.37 | 357.02 | 323.18 | 231.50 | 93.98 | 31.00 | — |
Average Common Equity |
384.05 | 341.49 | 238.91 | 232.08 | 42.10 | (163.37) | (163.37) | — |
Columns are period end dates